Usher综合征分子诊断的患病率及协调护理的需求
回顾性分析198例疑似Usher综合征患者的病历,190例(96%)符合临床诊断标准,67例(35%)获得致病性分子诊断。分子诊断平均年龄:USH1B为20岁、USH2A为37岁、USH2C为50岁。67例中23例(34%)建立眼科护理,其中8例(11%)建立听力学护理。作者认为分子检测应纳入常规护理以促进早期干预和多学科协调。
要点
- 198例疑似Usher综合征患者中190例(96%)符合临床诊断,67例(35%)获得分子诊断。
- 分子诊断平均年龄:USH1B为20岁、USH2A为37岁、USH2C为50岁。
- 67例分子诊断患者中仅23例(34%)建立眼科护理,8例(11%)建立听力学护理。
核心结论
- 作者认为分子检测和诊断应成为Usher综合征患者常规护理的一部分,以促进早期干预和眼科与听力学之间的协调护理。
研究设计与样本
- 回顾性病历复习,纳入198例因疑似Usher综合征就诊于Bascom Palmer Eye Institute(BPEI)视网膜色素变性门诊的个体,收集人口学信息、Usher综合征临床诊断、分子检测、分子诊断和听力学数据。
主要发现
- 198例中190例(96%)符合Usher综合征临床标准并获得临床诊断。
- 67例(35%)进行了基因检测并获得致病性分子诊断。
- 分子诊断平均年龄:USH1B为20岁、USH2A为37岁、USH2C为50岁。
- 67例分子诊断患者中,23例(34%)建立眼科护理,其中8例(11%)建立听力学护理。
关键数值与推荐
- Usher综合征临床诊断依据为视网膜色素变性(RP)合并感音神经性听力损失(SNHL)。
- 亚型(USH1、USH2、USH3)由严重程度和发病年龄决定,分子检测可进一步按致病基因区分亚型。
临床怎么用
- 作者认为分子检测和诊断应作为Usher综合征常规护理的一部分,以促进早期干预和眼科与听力学协调护理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Usher syndrome (USH) is a rare, autosomal-recessive genetic disorder and a leading cause of early onset deaf-blindness. A clinical diagnosis is made by the presence of retinitis pigmentosa (RP) with sensorineural hearing loss (SNHL). Subtype (USH1, USH2, USH3) is determined by severity and age of onset. Molecular testing is able to further distinguish USH subtypes by causative gene. As gene therapy strategies continue to be explored for USH, it is important to know the underlying genetic cause and to coordinate care among an interdisciplinary team. METHODS: We reviewed charts of 198 individuals presenting to the RP clinic at Bascom Palmer Eye Institute (BPEI) for suspected USH. Demographic information, USH clinical diagnosis, molecular testing, molecular diagnosis, and audiological data were collected. RESULTS: Of the 198 patients reviewed, 190 (96%) met clinical criteria for USH and received a clinical diagnosis. There were 67 (35%) that had a genetic test with a pathogenic molecular diagnosis. The average ages at molecular diagnosis were USH1B, 20 years old; USH2A, 37 years old; USH2C, 50 years old. Of the 67 with a molecular diagnosis, 23 (34%) established ophthalmic care and 8 of these (11%) established audiological care. DISCUSSION/CONCLUSION: Molecular testing and diagnosis should be part of the routine care of USH individuals to facilitate earlier interventions and coordinated care between ophthalmology and audiology. LEVEL OF EVIDENCE: 4 Laryngoscope, 135:1777-1780, 2025.
引用
- Colbert BM, Smeal M, Cromar ZJ, et al. Prevalence of Molecular Diagnoses for Usher Syndrome and the Need for Coordinated Care. Laryngoscope. 2024. PMID: 39560289. doi:10.1002/lary.31911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。